Factor XI Program: This initiative aims to develop a safer anticoagulant using two antibodies targeting Factor XI, leveraging genetic data for improved safety profiles. Regeneron’s acquisition ...

FusionLayer, a leading innovator in cloud infrastructure solutions, proudly announces its membership in the Open Programmable Infrastructure (OPI) Project, fostering an open ecosystem for ...

Slovakia's COVID-19 vaccine sceptic prime minister said on Monday that his country would challenge the adoption of a ...

Erik Wexler stepped into the top leadership role at 51-hospital Providence at a “tumultuous” time in healthcare, as he ...

Bay Area News Group: Live Organ Donations Are Growing In The U.S., California And Bay Area, But So Is The Need Since 2014, more than 500,000 people in the U.S. have donated organs, 200,000 of ...

Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.